ReGen’s ColostrininTM Moves to Convenient Daily Dosing Regimen in North America

Share Article

ReGen Therapeutics Limited ('ReGen' or the 'Company) is pleased to announce that Metagenics Inc., its exclusive licensee for ColostrininTM in North America, has now changed the recommended dosage regimen of its formulated product (CognisureTM) to one tablet per day. In North America ColostrininTM is marketed as a nutritional supplement to 'support healthy brain aging and cognition in humans' under the brand name CogniSureTM. Each convenient, chocolate-flavoured chewable tablet contains a daily dose of 100 mcg of Colostrinin. The recommended patient price for a 30-day supply is $29.95. In North America CognisureTM is available exclusively through licensed health care providers that offer professional quality Metagenics products.

“A large body of cellular research demonstrates that Colostrinin may influence numerous activities associated with normal brain aging - including those related to genetic expression, antioxidant mechanisms, and immune function”

ReGen Therapeutics Limited ('ReGen' or the 'Company) is pleased to announce that Metagenics Inc., its exclusive licensee for ColostrininTM in North America, has now changed the recommended dosage regimen of its formulated product (CognisureTM) to one tablet per day. In North America ColostrininTM is marketed as a nutritional supplement to 'support healthy brain aging and cognition in humans' under the brand name CogniSureTM. Each convenient, chocolate-flavoured chewable tablet contains a daily dose of 100 mcg of Colostrinin. The recommended patient price for a 30-day supply is $29.95. In North America CognisureTM is available exclusively through licensed health care providers that offer professional quality Metagenics products.

Supporting mental function in the aging process is a vital part of maintaining independent living and quality of life, and brain aging may begin sooner than has been previously assumed. Fortunately, it is now recognized that neurological aging is no longer a "fixed" sequence of events. Throughout life, the brain has a remarkable adaptability to help maintain important cognitive functions like memory and learning.

"This 'neuroplasticity' of the brain may be positively influenced by environmental factors, including exercise, dietary modifications, and nutrition,” said Jeff Bland, PhD, FACN, FACB, the Chief Science Officer for Metagenics, Inc. "Implementing strategies for healthy brain aging may be indicated much earlier than current practices."

“A large body of cellular research demonstrates that Colostrinin may influence numerous activities associated with normal brain aging - including those related to genetic expression, antioxidant mechanisms, and immune function,” commented Bland. “Three well-designed clinical studies have shown its effectiveness in supporting cognitive function in adults.”

Commenting on this development Mr.Tim Shilton, CEO of ReGen said: "This is very good news. In-market feedback has suggested that this should improve patient compliance and therefore market penetration."    

To date ColostrininTM is marketed as a nutritional supplement to 'support healthy brain aging and cognition in humans' in the US, Canada, Australia, Poland, Cyprus, UK, Turkey and India. LG Life Sciences, Ltd ('LGLS') has also been appointed as the exclusive distributor of ColostrininTM in South Korea subject to import and regulatory approval being obtained. ReGen are currently seeking licensees in other regions of the world (http://www.regentherapeutics.com).

About Metagenics, Inc.
Metagenics, Inc. (http://www.metagenics.com) is a nutrigenomics and lifestyle medicine company focused on reversing chronic illness and improving health. Founded in 1983, Metagenics serves more than 75,000 healthcare providers worldwide through premium quality, science-based medical foods, nutritional formulas, and lifestyle therapy programs to help their patients achieve a lifetime of good health.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tim Shilton
Regen Therapeutics Limited
44 0207 153 4920 ext. n/a
Email >
Visit website